Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Alice Long

Showing results (71-80 of 76) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 76 results.
The Journal of Clinical Investigation|July 21, 2015
Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patientsMark R Rigby, Kristina M Harris, Ashley Pinckney, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology|May 24, 2022
Chemokines, soluble PD-L1, and immune cell hyporesponsiveness are distinct features of SARS-CoV-2 critical illnessEric D Morrell, Pavan K Bhatraju, Neha A Sathe, et al.
Diabetes Care|November 23, 2019
Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 DiabetesManuela Battaglia, Simi Ahmed, Mark S Anderson, et al.
Diabetes|January 21, 2026
Phase I Clinical Trial of Islet Antigen-Specific Plasmid Coexpressing Tolerogenic Proteins Demonstrates Safety in Adults With Type 1 DiabetesCarla J Greenbaum, S Alice Long, Stephen E Gitelman, et al.
JCI Insight|November 8, 2021
IL-6 receptor blockade does not slow β cell loss in new-onset type 1 diabetesCarla J Greenbaum, Elisavet Serti, Katharina Lambert, et al.
Nature Medicine|October 4, 2023
Second international consensus report on gaps and opportunities for the clinical translation of precision diabetes medicineDeirdre K Tobias, Jordi Merino, Abrar Ahmad, et al.
Pageof 8

Showing results (71-80 of 76) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 76 results.
The Journal of Clinical Investigation|July 21, 2015
Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patientsMark R Rigby, Kristina M Harris, Ashley Pinckney, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology|May 24, 2022
Chemokines, soluble PD-L1, and immune cell hyporesponsiveness are distinct features of SARS-CoV-2 critical illnessEric D Morrell, Pavan K Bhatraju, Neha A Sathe, et al.
Diabetes Care|November 23, 2019
Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 DiabetesManuela Battaglia, Simi Ahmed, Mark S Anderson, et al.
Diabetes|January 21, 2026
Phase I Clinical Trial of Islet Antigen-Specific Plasmid Coexpressing Tolerogenic Proteins Demonstrates Safety in Adults With Type 1 DiabetesCarla J Greenbaum, S Alice Long, Stephen E Gitelman, et al.
JCI Insight|November 8, 2021
IL-6 receptor blockade does not slow β cell loss in new-onset type 1 diabetesCarla J Greenbaum, Elisavet Serti, Katharina Lambert, et al.
Nature Medicine|October 4, 2023
Second international consensus report on gaps and opportunities for the clinical translation of precision diabetes medicineDeirdre K Tobias, Jordi Merino, Abrar Ahmad, et al.
Pageof 8